Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain

[1]  J. Ramos-Rincón,et al.  Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapies , 2022, Journal of viral hepatitis.

[2]  J. Ramos-Rincón,et al.  Trends in hospitalizations and deaths in HIV-infected patients in Spain over two decades , 2021, AIDS.

[3]  H. Gendelman,et al.  Ultra-long-acting (XLA) antivirals for chronic viral hepatitis , 2021, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[4]  F. Zoulim,et al.  Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. , 2021, Journal of hepatology.

[5]  Kyong‐Mi Chang,et al.  Prospects for the Global Elimination of Hepatitis B. , 2021, Annual review of virology.

[6]  V. Soriano,et al.  Envisioning a hepatitis delta cure with new antivirals. , 2021, Future microbiology.

[7]  D. Sinn,et al.  Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response , 2021, Journal of Viral Hepatitis.

[8]  R. Jiménez-García,et al.  Sex-related disparities in the incidence and outcomes of hemorrhagic stroke among type 2 diabetes patients: a propensity score matching analysis using the Spanish National Hospital Discharge Database for the period 2016–18 , 2021, Cardiovascular Diabetology.

[9]  Udani Samarasekera.  Urgent action needed to eliminate viral hepatitis by 2030. , 2021, The lancet. Gastroenterology & hepatology.

[10]  H. Fukuda,et al.  Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection , 2021, Medicine.

[11]  J. Crespo.  Screening guide for hepatitis C virus infection in Spain. , 2021, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[12]  S. Ahn,et al.  Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals , 2020, Cancers.

[13]  C. Yurdaydın,et al.  Hepatitis Delta Virus Epidemiology in the Industrialized World. , 2020, AIDS reviews.

[14]  J. Borghi,et al.  Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. , 2020, The lancet. Gastroenterology & hepatology.

[15]  J. Lazarus,et al.  Progress towards elimination goals for viral hepatitis , 2020, Nature Reviews Gastroenterology & Hepatology.

[16]  A. Amato-Gauci,et al.  Mortality from liver diseases attributable to hepatitis B and C in the EU/EEA – descriptive analysis and estimation of 2015 baseline , 2020, Infectious diseases.

[17]  Y. Lim,et al.  Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  C. de Martel,et al.  The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis , 2020, Journal of hepatology.

[19]  J. Eiros,et al.  Hospital admissions in individuals with HTLV-1 infection in Spain. , 2020, AIDS.

[20]  Z. Younossi,et al.  Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD , 2020, Hepatology.

[21]  Wayne Leigh,et al.  Baseline , 2020, Definitions.

[22]  V. Soriano,et al.  Advances in hepatitis B therapeutics , 2020, Therapeutic advances in infectious disease.

[23]  V. Wong,et al.  Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis , 2019, Alimentary pharmacology & therapeutics.

[24]  David L. Thomas.  Global Elimination of Chronic Hepatitis. , 2019, The New England journal of medicine.

[25]  R. Peeling,et al.  Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. , 2019, The lancet. Gastroenterology & hepatology.

[26]  J. Lazarus,et al.  Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. , 2018, Journal of hepatology.

[27]  V. Soriano,et al.  Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain , 2018, European journal of gastroenterology & hepatology.

[28]  S. Kottilil,et al.  Chronic Hepatitis B Infection: A Review , 2018, JAMA.

[29]  A. Tefferi,et al.  Prevention of liver cancer with new curative hepatitis C antivirals: Real‐world challenges , 2018, Cancer.

[30]  B. McMahon,et al.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.

[31]  M. Casado,et al.  Value and innovation of direct-acting antivirals: long-term health outcomes of the strategic plan for the management of hepatitis C in Spain. , 2017, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[32]  V. Soriano,et al.  Hepatitis delta and HIV infection. , 2017, AIDS.

[33]  Y. Ni,et al.  Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options , 2016, Nature Reviews Gastroenterology &Hepatology.

[34]  V. Soriano,et al.  Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients , 2014, AIDS.

[35]  V. Soriano,et al.  Reduction in liver‐related hospital admissions and deaths in HIV‐infected patients since the year 2002 , 2006, Journal of viral hepatitis.

[36]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[37]  B. McMahon.  Chronic hepatitis B virus infection. , 2014, The Medical clinics of North America.

[38]  M. Manns,et al.  Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead , 2010, Nature Reviews Gastroenterology &Hepatology.

[39]  R. Jacobson,et al.  Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. , 2004, The New England journal of medicine.

[40]  A. B. Sukhomlinov,et al.  [Liver cirrhosis]. , 1989, Fel'dsher i akusherka.